Minirin (Desmopressin Acetate)

Desmopressin acetate mimics the natural hormone vasopressin and selectively activates V2 receptors in the kidney collecting ducts, promoting water reabsorption. It also stimulates endothelial cells to release factor VIII and von Willebrand factor, enhancing blood coagulation.

The appropriate dose of Minirin is individualized by the prescribing clinician based on the specific indication, patient age, weight, renal function, and response to therapy. Dosage adjustments may be required after monitoring clinical outcomes and laboratory values.

Safety data for desmopressin acetate in pregnancy and lactation are limited. Clinicians should weigh potential benefits against unknown risks and consider alternative therapies when possible. Breastfeeding mothers should consult their healthcare provider before use.

To order Minirin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Minirin (desmopressin) is a synthetic vasopressin analog with higher selectivity for V2 receptors, offering a longer duration of action and fewer vasoconstrictive side effects compared with natural vasopressin. This makes it preferable for chronic management of diabetes insipidus and nocturnal enuresis.

Minirin should be stored at temperatures below 25°C, protected from moisture and direct light. Keep the product in its original packaging until use and avoid freezing. Follow any additional handling instructions provided by the manufacturer.

Minirin is supplied as a sterile injectable solution and can be given intramuscularly, intravenously, or subcutaneously by a qualified healthcare professional. The route, volume, and frequency are determined by the prescriber according to the therapeutic indication.

The most serious risks include severe hyponatremia, which can lead to seizures or cerebral edema, and rare allergic reactions such as anaphylaxis. Patients should be monitored for signs of water intoxication and electrolyte disturbances throughout treatment.

Minirin is contraindicated in individuals with known hypersensitivity to desmopressin acetate, uncontrolled hypertension, or severe renal impairment that cannot be monitored. Caution is also advised for patients with a history of hyponatremia or those taking interacting medications.